• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

拉丁美洲心血管疾病和 COVID-19 注册研究:CARDIO COVID 19-20 注册研究的原理和设计。

Latin-American Registry of Cardiovascular Disease and COVID-19: Rationale and Design of the CARDIO COVID 19-20 Registry.

机构信息

Departamento de Cardiología de la Fundación Valle del Lili, CO.

Centro de Investigaciones Clínicas de la Fundación Valle del Lili, CO.

出版信息

Glob Heart. 2021 Feb 12;16(1):14. doi: 10.5334/gh.925.

DOI:10.5334/gh.925
PMID:33833938
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7894365/
Abstract

BACKGROUND

Infection caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) exhibits a strong infectivity but less virulence compared to severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS). In terms of cardiovascular morbidity, susceptible population include elderly and patients with certain cardiovascular conditions. This infection has been associated with cardiac injury, cardiovascular complications and higher mortality.

OBJECTIVES

The main objective of the CARDIO COVID 19-20 Registry is to determine the presence of cardiovascular comorbidities and cardiovascular complications in COVID-19 infected patients that required in-hospital treatment in different Latin American institutions.

METHODS

The CARDIO COVID 19-20 Registry is an observational, multicenter, ambispective, and hospital-based registry of patients with confirmed COVID-19 infection who required in-hospital treatment in Latin America. Enrollment of patients started on May 01, 2020 and was initially planned to last three months; based on the progression of pandemic in Latin America, enrollment was extended until December 2020, and could be extended once again based on the pandemic course in our continent at that moment.

CONCLUSIONS

The CARDIO COVID 19-20 Registry will characterize the in-hospital population diagnosed with COVID-19 in Latin America in order to identify risk factors for worsening of cardiovascular comorbidities or for the appearance of cardiovascular complications during hospitalization and during the 30-day follow up period.

摘要

背景

由 SARS-CoV-2(严重急性呼吸综合征冠状病毒 2)引起的感染具有很强的传染性,但与严重急性呼吸综合征(SARS)和中东呼吸综合征(MERS)相比,其毒力较弱。在心血管发病率方面,易感人群包括老年人和某些心血管疾病患者。这种感染与心脏损伤、心血管并发症和更高的死亡率有关。

目的

CARDIO COVID 19-20 登记处的主要目的是确定在不同拉丁美洲机构接受住院治疗的 COVID-19 感染患者中是否存在心血管合并症和心血管并发症。

方法

CARDIO COVID 19-20 登记处是一项观察性、多中心、前瞻性和基于医院的登记处,登记了在拉丁美洲因 COVID-19 感染而需要住院治疗的患者。患者的入组于 2020 年 5 月 1 日开始,最初计划持续三个月;根据拉丁美洲大流行的进展,入组时间延长至 2020 年 12 月,如果届时我们大陆的大流行情况仍然如此,可能会再次延长入组时间。

结论

CARDIO COVID 19-20 登记处将对拉丁美洲因 COVID-19 而住院的人群进行特征描述,以确定心血管合并症恶化或在住院期间和 30 天随访期间出现心血管并发症的风险因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2015/7894365/9f80b298902a/gh-16-1-925-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2015/7894365/9f80b298902a/gh-16-1-925-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2015/7894365/9f80b298902a/gh-16-1-925-g1.jpg

相似文献

1
Latin-American Registry of Cardiovascular Disease and COVID-19: Rationale and Design of the CARDIO COVID 19-20 Registry.拉丁美洲心血管疾病和 COVID-19 注册研究:CARDIO COVID 19-20 注册研究的原理和设计。
Glob Heart. 2021 Feb 12;16(1):14. doi: 10.5334/gh.925.
2
Latin-American Registry of Cardiovascular Disease and COVID-19: Final Results.拉丁美洲心血管疾病和 COVID-19 注册研究:最终结果。
Glob Heart. 2023 Nov 1;18(1):60. doi: 10.5334/gh.1272. eCollection 2023.
3
SARS-CoV 2 Infection (Covid-19) and Cardiovascular Disease in Africa: Health Care and Socio-Economic Implications.SARS-CoV-2 感染(COVID-19)与非洲心血管疾病:医疗保健和社会经济影响。
Glob Heart. 2021 Mar 15;16(1):18. doi: 10.5334/gh.829.
4
Cardiovascular and Cerebrovascular Complications With COVID-19.COVID-19 相关心血管和脑血管并发症。
Cardiol Rev. 2021;29(3):143-149. doi: 10.1097/CRD.0000000000000385.
5
Analysis of influence of background therapy for comorbidities in the period before infection on the risk of the lethal COVID outcome. Data from the international ACTIV SARS-CoV-2 registry («Analysis of chronic non-infectious diseases dynamics after COVID-19 infection in adult patients SARS-CoV-2»).分析感染前合并症的背景治疗对新冠致死结局风险的影响。数据来自国际 ACTIV SARS-CoV-2 注册中心(“分析成年 SARS-CoV-2 感染者感染后慢性非传染性疾病动态”)。
Kardiologiia. 2021 Sep 30;61(9):20-32. doi: 10.18087/cardio.2021.9.n1680.
6
COVID-19 and Multisystem Inflammatory Syndrome in Latin American Children: A Multinational Study.COVID-19 与拉丁美洲儿童多系统炎症综合征:一项跨国研究。
Pediatr Infect Dis J. 2021 Jan;40(1):e1-e6. doi: 10.1097/INF.0000000000002949.
7
Prevalence of Clinical and Subclinical Myocarditis in Competitive Athletes With Recent SARS-CoV-2 Infection: Results From the Big Ten COVID-19 Cardiac Registry.近期感染 SARS-CoV-2 的竞技运动员中临床和亚临床心肌炎的患病率:Big Ten COVID-19 心脏登记研究结果。
JAMA Cardiol. 2021 Sep 1;6(9):1078-1087. doi: 10.1001/jamacardio.2021.2065.
8
Latin American registry of renal involvement in COVID-19 disease. The relevance of assessing proteinuria throughout the clinical course.拉丁美洲 COVID-19 疾病肾脏受累登记研究。在整个临床病程中评估蛋白尿的相关性。
PLoS One. 2022 Jan 27;17(1):e0261764. doi: 10.1371/journal.pone.0261764. eCollection 2022.
9
Cardiac complications in patients hospitalised with COVID-19.COVID-19 住院患者的心脏并发症。
Eur Heart J Acute Cardiovasc Care. 2020 Dec;9(8):817-823. doi: 10.1177/2048872620974605. Epub 2020 Nov 21.
10
An Overview on COVID-19 and its Effect on Cardiovascular Diseases.关于 COVID-19 及其对心血管疾病影响的概述。
Endocr Metab Immune Disord Drug Targets. 2021;21(11):1949-1953. doi: 10.2174/1871530321999201228214718.

引用本文的文献

1
Two-year follow-up of patients with myocardial injury during acute COVID-19: insights from the CARDIO COVID 20-21 registry.急性新冠肺炎期间心肌损伤患者的两年随访:来自CARDIO COVID 20 - 21注册研究的见解
Front Cardiovasc Med. 2025 Jun 11;12:1584732. doi: 10.3389/fcvm.2025.1584732. eCollection 2025.
2
Genetic variants in influence SARS-CoV-2 infection susceptibility within Mexican Mestizos.基因变异影响墨西哥梅斯蒂索人对新冠病毒的感染易感性。
Front Genet. 2025 Apr 14;16:1558189. doi: 10.3389/fgene.2025.1558189. eCollection 2025.
3
Biochemical differences based on sex and clusters of biomarkers in patients with COVID-19: analysis from the CARDIO COVID 19-20 registry.

本文引用的文献

1
Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people.ACE 抑制剂和血管紧张素受体阻滞剂与严重 COVID-19 疾病风险:包括 830 万人的队列研究。
Heart. 2020 Oct;106(19):1503-1511. doi: 10.1136/heartjnl-2020-317393. Epub 2020 Jul 31.
2
Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial.继续或暂停血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂:对住院严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2)患者不良结局的影响——BRACE CORONA 试验。
Am Heart J. 2020 Aug;226:49-59. doi: 10.1016/j.ahj.2020.05.002. Epub 2020 May 13.
3
新型冠状病毒肺炎患者基于性别和生物标志物簇的生化差异:来自CARDIO COVID 19-20注册研究的分析
BMC Cardiovasc Disord. 2025 Mar 5;25(1):147. doi: 10.1186/s12872-025-04565-3.
4
Impact of myocardial injury on cardiovascular complications in hospitalized patients with COVID-19: insights from Latin America.心肌损伤对COVID-19住院患者心血管并发症的影响:来自拉丁美洲的见解。
Front Cardiovasc Med. 2025 Feb 17;12:1545142. doi: 10.3389/fcvm.2025.1545142. eCollection 2025.
5
Marked Global Differences in Mortality in Male Patients with COVID-19: An Analysis of the CARDIO COVID 19-20 and WHF COVID-19 CVD Studies.新冠病毒病男性患者死亡率的显著全球差异:CARDIO COVID 19 - 20和WHF COVID - 19心血管疾病研究分析
Glob Heart. 2025 Feb 28;20(1):21. doi: 10.5334/gh.1403. eCollection 2025.
6
Cardiovascular Outcomes in Hospitalized Patients with COVID-19: Does Age Really Matter?新冠肺炎住院患者的心血管结局:年龄真的重要吗?
J Cardiovasc Dev Dis. 2025 Jan 24;12(2):41. doi: 10.3390/jcdd12020041.
7
Long COVID Clusters of Symptoms Persist beyond Two Years after Infection: Insights from the CARDIO COVID 20-21 Registry.感染后两年以上仍存在长期新冠症状群:CARDIO COVID 20-21 注册研究的启示。
Viruses. 2024 Jun 26;16(7):1028. doi: 10.3390/v16071028.
8
Pre-Existing Atrial Fibrillation in Hospitalized Patients with COVID-19: Insights from the CARDIO COVID 19-20 Registry.COVID-19住院患者的既往房颤:来自CARDIO COVID 19-20注册研究的见解
J Cardiovasc Dev Dis. 2024 Jul 4;11(7):210. doi: 10.3390/jcdd11070210.
9
Cardiovascular Complications in Patients with Heart Failure and COVID-19: CARDIO COVID 19-20 Registry.心力衰竭合并新型冠状病毒肺炎患者的心血管并发症:CARDIO COVID 19-20注册研究
J Cardiovasc Dev Dis. 2024 Jan 23;11(2):34. doi: 10.3390/jcdd11020034.
10
Latin-American Registry of Cardiovascular Disease and COVID-19: Final Results.拉丁美洲心血管疾病和 COVID-19 注册研究:最终结果。
Glob Heart. 2023 Nov 1;18(1):60. doi: 10.5334/gh.1272. eCollection 2023.
Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China.新冠肺炎住院患者中心脏损伤与死亡的相关性研究:中国武汉。
JAMA Cardiol. 2020 Jul 1;5(7):802-810. doi: 10.1001/jamacardio.2020.0950.
4
Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic.心血管考虑因素在 COVID-19 大流行期间的患者、医护人员和卫生系统。
J Am Coll Cardiol. 2020 May 12;75(18):2352-2371. doi: 10.1016/j.jacc.2020.03.031. Epub 2020 Mar 19.
5
Coronaviruses and the cardiovascular system: acute and long-term implications.冠状病毒与心血管系统:急性和长期影响
Eur Heart J. 2020 May 14;41(19):1798-1800. doi: 10.1093/eurheartj/ehaa231.
6
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素:一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
7
The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.2019 冠状病毒病(COVID-19)疫情的起源、传播和临床治疗——现状更新。
Mil Med Res. 2020 Mar 13;7(1):11. doi: 10.1186/s40779-020-00240-0.
8
COVID-19 in Latin America: The implications of the first confirmed case in Brazil.拉丁美洲的新冠疫情:巴西首例确诊病例的影响。
Travel Med Infect Dis. 2020 May-Jun;35:101613. doi: 10.1016/j.tmaid.2020.101613. Epub 2020 Feb 29.
9
An interactive web-based dashboard to track COVID-19 in real time.一个基于网络的交互式仪表盘,用于实时追踪新冠病毒。
Lancet Infect Dis. 2020 May;20(5):533-534. doi: 10.1016/S1473-3099(20)30120-1. Epub 2020 Feb 19.
10
Pathogenicity and transmissibility of 2019-nCoV-A quick overview and comparison with other emerging viruses.2019-nCoV 的致病性和传染性:快速概述及与其他新兴病毒的比较
Microbes Infect. 2020 Mar;22(2):69-71. doi: 10.1016/j.micinf.2020.01.004. Epub 2020 Feb 4.